Roche reported a strong start to the year with group sales up 6% at constant exchange rates. Pharmaceuticals Division saw a 7% increase in sales at CER, driven by strong growth in key medicines. Diagnostics Division sales rose 3% at CER, despite headwinds from China's healthcare reforms. Several products like Xolair and Hemlibra were significant growth drivers. Roche highlighted positive clinical data for various treatments, including those for multiple sclerosis and obesity. A new Elecsys NfL blood test was approved, and the cobas MPX-E assay was launched. The company entered an agreement to acquire SAGA Diagnostics to enhance their oncology diagnostics. Roche's CEO expressed confidence in sustained future growth. The company confirmed its 2026 outlook, expecting mid-single-digit sales growth at CER. They also aim for core earnings per share growth in the high single digits (CER) and plan to increase the dividend. Key geographical regions showed varying sales performance, with the U.S. and Japan performing well. Positive data was announced for various drug trials in breast cancer, lupus, obesity, and multiple sclerosis.